Brief: Mira Pharmaceuticals In Discussions With Memorial Sloan Kettering To Collaborate On Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
21/05/2024 14:07
May 21 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS IN DISCUSSIONS WITH MEMORIAL SLOAN
KETTERING TO COLLABORATE ON PRECLINICAL CANCER PAIN MODEL
UTILIZING THE COMPANY'S NOVEL ORAL KETAMINE ANALOG
Source text for Eikon: ID:nPn1Nbl2ga
Further company coverage: MIRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing